Home > Gastroenterology > DDW 2022 > IBD > Biologic treatment decreases dementia risk in senior IBD patients

Biologic treatment decreases dementia risk in senior IBD patients

Presented By
Dr Ahmed Eltelbany, Cleveland Clinic, OH, USA
Presented by
Ahmed Eltelbany Cleveland Clinic
Conference
DDW 2022
Doi
https://doi.org/10.55788/c9f10dda
A retrospective study on inflammatory bowel disease (IBD) in patients aged >65 years revealed that patients with IBD have a higher prevalence of dementia compared with the general population. Interestingly, in those treated with biologics, dementia was significantly less prevalent than in IBD patients not on biologic treatment. Emerging evidence has identified the so-called gut-brain axis that includes metabolic, endocrine, and neural signalling as communication between the intestine and the central nervous system. Thus, a study point of interest is a possible difference in the prevalence of dementia in those with and without IBD. Healthcare information on over 7.5 million US patients served as a data source to investigate the presence of dementia in older patients with IBD [1]. Between 2016 and 2022, the study included patients who were over 65 years of age, of whom 41,860 had a diagnosis of Crohn’s disease (CD)...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on